We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
2 own
4 watching
Current Price
$24.15
$-0.35
(-1.43%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
2,120.74M
52-Week High
28.115
52-Week Low
14.08
Average Volume
1.63M
Dividend Yield
--
P/E Ratio
--
Market Capitalization2,120.74M
52-Week High28.115
52-Week Low14.08
Average Volume1.63M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, high-value frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Market News Video
3 months ago
In trading on Thursday, shares of Revolution Medicines Inc (RVMD) crossed below their 200 day moving average of 22.46, changing hands as low as 22.34 per share. Revolution Medicines Inc shares are currently trading down about 2.1% on the day...
Globe Newswire
4 months ago
REDWOOD CITY, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the pricing of its underwritten public offering of 11,500,000 shares of common stock at a ...
Ticker Report
6 months ago
Bank of America initiated coverage on shares of Revolution Medicines (NASDAQ:RVMD Get Rating) in a report published on Friday morning, Marketbeat.com reports. The firm issued a neutral rating and a $24.00 target price on the stock. RVMD has been the topic of several other reports. HC ...
Ticker Report
7 months ago
DekaBank Deutsche Girozentrale lifted its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD Get Rating) by 2.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities Exchange Commission. The institutional investor owned 21,600 ...
Zolmax
7 months ago
Revolution Medicines (NASDAQ:RVMD Get Rating) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a research report issued on Saturday, Zacks.com reports. According to Zacks, Revolution Medicines Inc. is a clinical-stage oncology company. It is focused on developing ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$24.15
$-0.35
(-1.43%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00